1 Global Public-Private Partnerships for Pharmaceuticals: Operational and Normative Features, Challenges, and Prospects1,2

Global public-private partnerships (GPPPs) in health have been created, purportedly, as a response to both market and government failure to provide health care goods and services, particularly in developing countries. They have been created to address issues of product development (vaccines or pharmaceuticals), improve access to healthcare products, assist with global coordination mechanisms, strengthen health care services, provide public advocacy and education, and for regulatory and quality assurance purposes. This paper provides an overview of the emerging features of global public-private partnerships in health and argues that GPPPs have real and potential normative and operational implications for national and global health governance. The paper examines two global public-private partnerships in HIV/AIDS-related pharmaceuticals provision: the Accelerated Access Initiative and the Diflucan Partnership Program. It concludes by considering the prospects and challenges of GPPPs as a mechanism of global health governance in advancing health as a global public good